drugset
drugset / Trial / NCT03292952

KP415 Classroom Study in Children (6-12 Years of Age) With ADHD

NCT03292952 ↗

Phase 3 Completed 155 enrolled Zevra Therapeutics
RandomizedParallel-groupQuadruple-blindTreatment

Summary

The study is a multicenter, dose-optimized, double-blind, randomized, placebo-controlled, parallel efficacy laboratory classroom study with KP415 in children with Attention-Deficit/Hyperactivity Disorder (ADHD).

Timeline

Start
2017-12-20
Primary completion
2018-05-16
Completion
2018-05-16

Drugs

EvaluationDrugModalityDoseRoute
Subject Serdexmethylphenidate Small molecule 28 mg Oral
Subject Serdexmethylphenidate Small molecule 42 mg Oral
Subject Serdexmethylphenidate Small molecule 56 mg Oral
Subject dexmethylphenidate Unknown 6 mg Oral
Subject dexmethylphenidate Unknown 9 mg Oral
Subject dexmethylphenidate Unknown 12 mg Oral

Indications

attention deficit-hyperactivity disorder